- Home
- CTMX vs ARVN Comparison
CTMX vs ARVN Comparison
Compare CTMX & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- ARVN
- Stock Information
- Founded
- CTMX 2008
- ARVN 2015
- Country
- CTMX United States
- ARVN United States
- Employees
- CTMX N/A
- ARVN N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- CTMX Health Care
- ARVN Health Care
- Exchange
- CTMX Nasdaq
- ARVN Nasdaq
- Market Cap
- CTMX 596.2M
- ARVN 676.2M
- IPO Year
- CTMX 2015
- ARVN 2018
- Fundamental
- Price
- CTMX $3.64
- ARVN $12.82
- Analyst Decision
- CTMX Strong Buy
- ARVN Buy
- Analyst Count
- CTMX 6
- ARVN 23
- Target Price
- CTMX $6.50
- ARVN $17.80
- AVG Volume (30 Days)
- CTMX 3.9M
- ARVN 3.1M
- Earning Date
- CTMX 11-06-2025
- ARVN 11-05-2025
- Dividend Yield
- CTMX N/A
- ARVN N/A
- EPS Growth
- CTMX 50.22
- ARVN N/A
- EPS
- CTMX 0.24
- ARVN N/A
- Revenue
- CTMX $113,631,000.00
- ARVN $312,300,000.00
- Revenue This Year
- CTMX N/A
- ARVN N/A
- Revenue Next Year
- CTMX N/A
- ARVN N/A
- P/E Ratio
- CTMX $15.28
- ARVN N/A
- Revenue Growth
- CTMX N/A
- ARVN 93.86
- 52 Week Low
- CTMX $0.40
- ARVN $5.90
- 52 Week High
- CTMX $4.62
- ARVN $27.00
- Technical
- Relative Strength Index (RSI)
- CTMX 50.34
- ARVN 74.49
- Support Level
- CTMX $3.35
- ARVN $10.00
- Resistance Level
- CTMX $4.45
- ARVN $11.51
- Average True Range (ATR)
- CTMX 0.37
- ARVN 0.73
- MACD
- CTMX -0.06
- ARVN 0.16
- Stochastic Oscillator
- CTMX 30.00
- ARVN 71.92
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.